US › Healthcare

Virax Biolabs Group Limited Ordinary Shares (VRAX)

US · Healthcare · Biotechnology

$1.45-10.49%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$12,423

Revenue YoY

-84.5%

Net profit

$-5.0M

Net margin

-40,439.1%

Key statistics

Market cap

$2.0M

Forward P/E

0.0

P/B

0.26

Book value

$13.08

EPS (TTM)

$-12.64

52-week high

$21.75

52-week low

$1.38

50-day MA

$2.52

200-day MA

$4.30

Beta

1.39

Analyst view

with an average price target of $25.00.

Shareholding

Insiders

1.58%

Institutions

1.99%

Largest institutional holders

Fund	Stake
Jane Street Group LLC	1.96%
UBS Group AG	0.00%
NATIONAL BANK OF CANADA /FI/	0.00%
Jump Financial LLC	0.00%
Armistice Capital, LLC	0.00%
Advisor Group Holdings, Inc.	0.00%
XTX Topco Ltd	0.00%
Northwestern Mutual Wealth Management Co	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Virax Biolabs Group Limited Ordinary Shares — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.